InvestorWire NewsRoom

InvestorNewsBreak

InvestorNewsBreaks – Clearside Biomedical Inc. (NASDAQ: CLSD) Closes Sale of Common Stock for $12M
January 28, 2021

InvestorNewsBreaks – Clearside Biomedical Inc. (NASDAQ: CLSD) Closes Sale of Common Stock for $12M

Clearside Biomedical (NASDAQ: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced that it has closed the sale of 4,209,050 shares of common stock. The shares were priced at $2.851 per share, with the sale resulting in approximately $12 million. In the announcement, Clearside noted that the sale took place with institutional investors and certain existing stockholders. Clearside is recognized for its proprietary SCS Microinjector(R), designed to combat sight-threatening disease. The SCS Microinjector targets the suprachoroidal space (“SCS”) and provides access to the macula, retina and choroid. The sole placement agent for the offering was Roth Capital Partners.

To view the full press release, visit https://ibn.fm/X1qzU

About Clearside Biomedical Inc.

Clearside Biomedical is a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases. Clearside’s proprietary SCS Microinjector(R) targets the suprachoroidal space (“SCS”) and offers unique access to the macula, retina and choroid where sight-threatening disease often occurs. Clearside’s SCS injection platform is an inherently flexible, in-office, nonsurgical procedure, intended to provide targeted delivery to the site of disease and to work with both established and new formulations of medications, as well as future therapeutic innovations such as gene therapy. For more information about the company, please visit www.ClearsideBio.com.  

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Recent NewsBreaks

NewsBreaks Categories

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(862) 930-1404

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).